Drug Profile


Alternative Names: ABC 12/3; ALT 07; Ansimar; DO 309; Maxivent

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ABC
  • Developer Abbott GmbH & Co. KG; ABC; Alitair Pharmaceuticals Inc; sanofi-aventis
  • Class Antiasthmatics; Antitussives; Bronchodilators; Small molecules; Xanthines
  • Mechanism of Action Phosphoric diester hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bronchiectasis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma; Bronchitis; Chronic obstructive pulmonary disease
  • No development reported Bronchiectasis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bronchiectasis in USA (PO)
  • 14 Feb 2014 Doxofylline receives Orphan Drug status for Bronchiectasis in USA (PO)
  • 07 May 2013 Doxofylline licensed to Alitair Pharmaceuticals in USA before May 2013 (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top